Ute Essner

Sativex ^® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial

Jolana Marková, Ute Essner, Bülent Akmaz et al. · International Journal of Neuroscience · 2018 · 135 citations

<p>Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry</p>

Michael A. Ueberall, Ute Essner, Gerhard Mueller-Schwefe · Journal of Pain Research · 2019 · 60 citations · Full text

Drug-resistant MS spasticity treatment with Sativex^®add-on and driving ability

M Freidel, Klaus Tiel‐Wilck, Herbert Schreiber et al. · Acta Neurologica Scandinavica · 2014 · 36 citations

Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)

Uwe K. Zettl, T. Henze, Ute Essner et al. · The European Journal of Health Economics · 2013 · 30 citations

Multiple Sclerosis Patients, Neurological Disorder, Mobility Improvement Study +8

Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial

Sven G. Meuth, T. Henze, Ute Essner et al. · International Journal of Neuroscience · 2020 · 26 citations